Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Dec. 13, 2024 (HealthDay News) — The addition of camrelizumab to neoadjuvant chemotherapy improves pathological complete response for patients with early or locally advanced triple-negative breast cancer, according to a study published online Dec. 13 in the Journal of the American Medical Association <\/em>to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.<\/p>\n Li Chen, M.D., from the Fudan University Shanghai Cancer Center, and colleagues examined the efficacy and adverse events of camrelizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy in a randomized, phase 3 trial involving 441 patients with early or locally advanced triple-negative breast cancer. Patients were randomly assigned to receive camrelizumab 200 mg or placebo combined with chemotherapy every two weeks (222 and 219 patients, respectively).<\/p>\n The researchers found that pathological complete response was achieved in 56.8 and 44.7 percent of patients in the camrelizumab-chemotherapy and the placebo-chemotherapy groups, respectively (rate difference, 12.2 percent). Adverse events of grade 3 or higher occurred in 89.2 and 83.1 percent of patients in the camrelizumab-chemotherapy and placebo-chemotherapy groups, respectively, in the neoadjuvant phase; serious adverse events occurred in 34.7 and 22.8 percent, respectively; and fatal adverse events occurred in 0.9 percent of those in the camrelizumab-chemotherapy group.<\/p>\n “The benefits of camrelizumab-chemotherapy with respect to pathologic complete response were generally consistent across subgroups,” the authors write.<\/p>\n This study was supported by Jiangsu Hengrui Pharmaceuticals, which manufactures camrelizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/p>\n